fintopic.
Docs Get the API

Biocon secures USFDA approval for Pebrilzo

5 statements from 3 sources, Nov 16, 2026 04:18 UTC to Nov 18, 2026 03:52 UTC
News
Updated
Front page

Statements (5)

  1. Bullish

    Biocon received European Commission market authorization for a biosimilar for breast cancer treatment.

    cnbctv18.comHigh importance
  2. Neutral

    Biocon's pertuzumab is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's new tailored clinical approach

    business-standard.com
  3. Bullish

    Biocon secures U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay) Injection, a biosimilar to Perjeta®.

    businesswire.comHigh importance
  4. Bullish

    Biocon shares gain after US FDA approves cancer drug biosimilar

    cnbctv18.comHigh importance
  5. Bullish

    Biocon received USFDA approval for Pebrilzo, its fifth cancer biosimilar

    business-standard.comHigh importance